Product Introduction
Trivolib 0.2/500/1 mg Tablet ER 10 is a combination antidiabetic medication manufactured by Sun Pharmaceutical Industries Ltd. It contains three active ingredients: Glimepiride 1 mg, Metformin Hydrochloride 500 mg, and Voglibose 0.2 mg. This extended-release formulation is designed to provide sustained blood sugar control in individuals with Type 2 diabetes mellitus.
Uses
- Management of Type 2 diabetes mellitus in adults when diet, exercise, and single-agent or dual therapy are insufficient to control blood glucose levels.
Benefits
- Glimepiride stimulates insulin release from the pancreas, lowering blood glucose levels.
- Metformin reduces hepatic glucose production and enhances insulin sensitivity.
- Voglibose delays carbohydrate digestion and absorption, reducing postprandial blood glucose spikes.
Composition
- Glimepiride – 1 mg
- Metformin Hydrochloride – 500 mg
- Voglibose – 0.2 mg
Side Effects
Common side effects may include:
- Nausea
- Diarrhea
- Abdominal pain
- Loss of appetite
- Metallic taste
- Hypoglycemia (low blood sugar)
In rare cases, serious side effects may occur, such as:
- Lactic acidosis (symptoms include fatigue, muscle pain, and difficulty breathing)
- Allergic reactions (rash, itching, swelling)
- Anemia or low blood cell counts
Safety Advice
- Pregnancy: Not recommended during pregnancy; consult your doctor for alternatives.
- Breastfeeding: Not recommended during breastfeeding; consult your doctor.
- Alcohol: Avoid alcohol as it may increase the risk of lactic acidosis and hypoglycemia.
- Kidney and Liver Function: Use with caution in patients with kidney or liver problems.
- Driving and Operating Machinery: May cause dizziness or drowsiness; exercise caution when driving or operating machinery.
